HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Puma Biotechnology (NASDAQ:PBYI) and maintained a $7 price target.

May 03, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Puma Biotechnology with a $7 price target.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Puma Biotechnology. This endorsement reaffirms the firm's confidence in Puma Biotechnology's potential, likely encouraging both current and potential investors about the stock's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100